Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Patent metadata

Field	Value
Publication number	US-10875902-B2
Application number	US-201916392898-A
Country	US
Kind code	B2
Filing date	Apr 24, 2019
Priority date	Apr 25, 2018
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

First claim

It is claimed:

1. A conjugate comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide, wherein the GLP-1 fusion peptide comprises a GLP-1 peptide, a first linker peptide, a hinge-Fc region peptide, and a second linker peptide and the GLP-1 fusion peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 113-224 and 267-274.

2. The conjugate of claim 1 , wherein the cyclic PYY peptide is represented by Formula I or a derivative or pharmaceutically acceptable salt thereof:

wherein
p is 0 or 1;
m is 0, 1, 2, 3, 4, or 5;
n is 1, 2, 3, or 4;
q is 0 or 1; provided that q is 1 only when Z 30 is absent;
BRIDGE is -Ph-CH 2 —S—, -triazolyl-, —NHC(O)CH 2 S—, —SCH 2 C(O)NH—, —(OCH 2 CH 2 ) 2 NHC(O)CH 2 S, —NHC(O)—, or —CH 2 S—;
Z 4 is K, A, E, S, or R;
Z 7 is A or K;
Z 9 is G or K;
Z 11 is D or K;
Z 22 is A or K;
Z 23 is S or K;
Z 26 is A or H;
Z 30 is L, W, or absent,
provided that Z 30 is absent only when q is 1;
Z 34 is

Z 35 is

wherein the derivative is the compound of Formula I that is modified by one or more processes selected from the group consisting of amidation, acylation, and pegylation.

3. The conjugate of claim 2 , wherein the cyclic PYY peptide is represented by Formula I or the derivative or pharmaceutically acceptable salt thereof, wherein:
p is 0 or 1;
m is 0, 1, 2, 3, 4, or 5;
n is 1, 2, 3, or 4;
q is 0 or 1; provided that q is 1 only when Z 30 is absent;
BRIDGE is -Ph-CH 2 —S—, -triazolyl-, —NHC(O)CH 2 S—, —SCH 2 C(O)NH 2 —, —(OCH 2 CH 2 ) 2 NHC(O)CH 2 S, —NHC(O)—, or —CH 2 S—;
Z 4 is K, A, E, S, or R;
Z 7 is A or K, wherein the amino side chain of said K is optionally substituted with

wherein i is an integer of 0 to 24, and X═Br, I or Cl, —C(O)CH 2 Br, —C(O)CH 2 I, or —C(O)CH 2 Cl;
Z 9 is G or K, wherein the amino side chain of said K is optionally substituted with

wherein i is an integer of 0 to 24, and X═Br, I or Cl, —C(O)CH 2 Br, —C(O)CH 2 I, or —C(O)CH 2 Cl;
Z 11 is D or K, wherein the amino side chain of said K is optionally substituted with

wherein i is an integer of 0 to 24, and X═Br, I or Cl, —C(O)CH 2 Br, —C(O)CH 2 I, or —C(O)CH 2 Cl;
Z 22 is A or K, wherein the amino side chain of said K is optionally substituted with

wherein i is an integer of 0 to 24, and X═Br, I or Cl, —C(O)CH 2 Br, —C(O)CH 2 I, or —C(O)CH 2 Cl;
Z 23 is S or K, wherein the amino side chain of said K is optionally substituted with

wherein i is an integer of 0 to 24, and X═Br, I or Cl, —C(O)CH 2 Br, —C(O)CH 2 I, or —C(O)CH 2 Cl;
Z 26 is A or H;
Z 30 is L;
Z 34 is

and
Z 35 is

4. The conjugate of claim 2 , wherein the cyclic PYY peptide is represented by Formula I or the derivative or pharmaceutically acceptable salt thereof, wherein:
p is 0 or 1;
m is 0, 1, 2, 3, or 5;
n is 1, 2, or 4;
q is 0 or 1; provided that q may be 1 only when Z 30 is absent;
BRIDGE is -Ph-CH 2 —S—, -triazolyl-, —NHC(O)CH 2 S—, —(OCH 2 CH 2 ) 2 NHC(O)CH 2 S, —NHC(O)—, or —CH 2 S—;
Z 4 is K, A, E, S, or R;
Z 7 is A or K, wherein the amino side chain of said K is substituted with —C(O)CH 2 Br,
Z 9 is G or K, wherein the amino side chain of said K is substituted with —C(O)CH 2 Br,
Z 11 is D or K, wherein the amino side chain of said K is substituted with —C(O)CH 2 Br,
Z 22 is A or K, wherein the amino side chain of said K is substituted with —C(O)CH 2 Br,
Z 23 is S or K, wherein the amino side chain of said K is substituted with —C(O)CH 2 Br,
Z 26 is A or H,
Z 30 is L;
Z 34 is

Z 35 is

5. The conjugate of claim 2 , wherein the cyclic PYY peptide is selected from the group consisting of SEQ ID NOs:1-54, or a pharmaceutically acceptable salt thereof.

6. The conjugate of claim 5 , wherein the cyclic PYY peptide is selected from SEQ ID NO:24, 25, 27, 28, 29, 30, 33, or 34, or a pharmaceutically acceptable salt thereof.

7. The conjugate of claim 2 , wherein the GLP-1 fusion peptide is covalently linked to the cyclic PYY peptide at a K residue of the cyclic PYY peptide.

8. The conjugate of claim 7 , wherein only one of Z 7 , Z 9 , Z 11 , Z 22 and Z 23 in Formula I is K, and the K is covalently linked to a cysteine residue in the second linker peptide of the GLP-1 fusion peptide.

9. The conjugate of claim 8 , wherein Z ii in Formula I is K.

10. The conjugate of claim 2 , wherein a cysteine residue between amino acid residues 287 to 289 of the GLP-1 fusion peptide is covalently linked to a K residue at residue Z 7 , Z 9 , Z 11 , Z 22 , or Z 23 of the cyclic PYY peptide via a chemical linker.

11. The conjugate of claim 1 , wherein the conjugate comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:225-262 or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

13. A method for treating or preventing a disease or disorder in a subject in need thereof, wherein said disease or disorder is obesity, type I or type II diabetes, metabolic syndrome, insulin resistance, impaired glucose tolerance, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypoglycemia due to congenital hyperinsulinism (CHI), dyslipidemia, atherosclerosis, diabetic nephropathy, hypertension, cardiovascular risk factors related to unmanaged cholesterol, cardiovascular risk factors related to lipid levels, osteoporosis, inflammation, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), renal disease, and/or eczema, the method comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 12 .

14. A method of reducing at least one of food intake or body weight in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 12 .

15. A kit comprising the conjugate of claim 1 and a device for injection.

16. A conjugate comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide, wherein the GLP-1 fusion peptide comprises the amino acid sequence of SEQ ID

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Zhang Yue-Mei
• Camacho Raul C
• Case Martin A
• Chi Ellen
• Edavettal Suzanne
• Edwards Wilson
• Norquay Lisa
• Wall Mark J
• Zhang Rui
• Zheng Songmao

Classifications

• A61P3/06 Primary

  Antihyperlipidemics · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C07K14/57545

  Neuropeptide Y · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title